MyDx, Inc. (OTCQB: $MYDX) Announces Top 10
Tracked Cannabis Therapies; Top 10 Patient Communities Supporting $Cannabis
Therapeutics
SAN DIEGO, CA - April 11, 2017 (Investorideas.com Newswire)
MyDx, Inc. (OTCQB: MYDX), a science and technology company and creator of MyDx®
(My Diagnostic), the first multi-use handheld chemical analyzer designed for
the Cannabis professional and retail consumer to correlate the chemical profile
of cannabis with its therapeutic effect, today announces the release of select
relevant datasets surrounding the top ailments that people are seeking relief
for, as well as the top patient communities that help each other identify a
chemical profile to treat certain ailments.
Top
10 Tracked Cannabis Therapies
Pain is the number one sought after therapy by the CannaDx
Community. Approximately 43% of the people testing and tracking a specific
cannabis chemical profile for relief are doing so to help treat their Pain.
Approximately 28% are seeking cannabis chemical profiles for Anxiety and
Depression, 18% for Migraines, 15% for Nausea, 14% for PTSD, 13% for Bipolar
Disorder, 12% for Anorexia, 11% for ADD/ADHD, and 6% for Arthritis.
Top
10 Patient Communities to Support Cannabis Therapeutics
Although Ulcers and Crones Disease represent less than 2.5% of
the crowdsourced ailments being tracked by our community of users combined, it
is interesting to note that over 93% of CannaDx users who are seeking a
chemical profile as relief for those ailments are sharing their findings with
the rest of the community. In comparison, the patient community support is not
as strong for Pain, where only about 20% of the population engages the CannaDx
community with their findings. In general, we have found that depending on the
nature of the disease, the more niche the patient community, the more users are
willing to help other people identify the ideal chemical profile to treat their
specific ailment.
Finding
a Chemical Profile that Works for You
In a recent article referenced in Forbes entitled Cannabis Lab
Testing Is The Industry's Dirty Little Secret, the challenge of testing,
tracking and finding the right chemical profile to meet a patient's needs
becomes even more compounded when one faces the reality that not all labs are
created equal, and even if they were, not all branded samples named 'Blue
Dream' have similar chemical profiles. This creates a serious problem when
people think they are buying a consistent cannabis product based on its name,
which at this point in the developing market, means very little.
"We are finally getting to heart of what aliments people
are tracking and more importantly, what unique chemicals profiles are helping
them find relief," stated Daniel Yazbeck, Chief Executive Officer of MyDx.
"By mining this HIPPA Compliant Data, we are now identifying the specific
green Active Pharmaceutical Ingredients (gAPI) that can be derived from
cannabis, as well as the dosage of each ingredient that should go into a
formulation so it can be tailored for a specific therapy. This information not
only supports an active engaged community, but also provides the basis for our
Company to partner, sell and supply smart devices and formulations to the
various communities we service so they can benefit from tailored cannabis
therapies that meet their specific needs."
As more data is accumulated and as formulations become
validated, MyDx intends to commercialize those remedies and have them more
readily available for mass consumption.
To Learn More about Cannabis Testing, MyDx Technology, and the
Science of Cannabis 2.0, please download the MyDx White Paper.
About
MyDx, Inc.
MyDx, Inc. (OTCQB: MYDX) is a chemical detection and sensor
technology company based in San Diego, California whose mission is to help
people Trust & Verify® what they put into their minds and bodies. The
Company developed MyDx®, a patented, affordable portable analyzer that provides
real-time chemical analysis and fits in the palm of the user's hand. The
multi-use MyDx analyzer leverages over a decade of established chemical
detection technology to measure chemicals of interest. The Company owns a
substantial and growing intellectual property portfolio of patents covering its
technology. The MyDx AquaDx®, OrganaDx™ and CannaDx™ sensors are now
commercialized, and the AeroDx® application is next in line. All sensors will
be compatible with a MyDx App that empowers consumers to live a healthier life
by revealing the chemical composition of what they eat, drink and inhale. For
more information, please visit www.cdxlife.com.
Forward-Looking Statements
This news release contains "forward-looking
statements" as that term is defined in Section 27(a) of the Securities Act
of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934,
as amended. Statements may contain certain forward-looking statements
pertaining to future anticipated or projected plans, performance and
developments, as well as other statements relating to future operations and
results. Any statements in this press release that are not statements of
historical fact may be considered to be forward-looking statements. Words such
as "may," "will," "expect," "believe,"
"anticipate," "estimate," "intends,"
"goal," "objective," "seek," "attempt,"
or variations of these or similar words, identify forward-looking statements.
These forward-looking statements by their nature are estimates of future
results only and involve substantial risks and uncertainties, including but not
limited to risks associated with the uncertainty of future financial results,
additional financing requirements, development of new products, our ability to
complete our product testing and launch our product commercially, the
acceptance of our product in the marketplace, the uncertainty of the laws and
regulations relating to cannabis, the impact of competitive products or
pricing, technological changes, the effect of economic conditions and other
uncertainties detailed from time to time in our reports filed with the
Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings
or www.sec.gov.
Investor
Contact:
MyDx Shareholder Communications
800.814.4550 ext. 4
ir@cdxlife.com
800.814.4550 ext. 4
ir@cdxlife.com
Watch the 420
Cannabis Investor video
More Info:
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
